Comparing the characteristics in INT-1 vs INT-2/high risk.
| Variables | All patients (N=57) |
INT-1 risk (N=33) |
INT-2/high risk (N=24) | |
|---|---|---|---|---|
| Age, median (range), years | 58 (23–80) | 58 (37–77) | 63.5 (23–80) | 0.13 |
| Gender, male (%) | 29 (50.9) | 19 (57.6) | 10 (41.7) | 0.29 |
| Etiology | 0.55 | |||
| Primary | 28 (49.2) | 18 (54.5) | 10 (41.7) | |
| Secondary | 29 (50.8) | 15 (45.5) | 14 (58.3) | |
| JAK2V617F, N (%) | 41 (71.9) | 24 (72.7) | 17 (70.8) | 0.66 |
| CALR, N (%) | 9 (15.8) | 7 (21.2) | 2 (8.3) | 0.16 |
| Previous use of , N (%) | ||||
| Hydroxyurea | 52 (91.2) | 31 (93.9) | 21 (87.5) | 0.64 |
| Thalidomide | 4 (7) | 1 (3) | 3 (12.5) | 0.30 |
| Interferon-alpha | 5 (8.8) | 1 (3) | 4 (16.7) | 0.15 |
| Erythropoietin | 2 (3.5) | 0 | 2 (8.3) | 0.17 |
| Splenectomy | 4 (7) | 2 (6) | 1 (4.1) | 1.0 |
| Pre-treatment spleen size, mean±SD, mm | 194±9.4 | 211±58.7 | 196±52 | 0.32 |
| Pre-treatment platelet count, median (range), ×103/μL | 366 (89–1,206) | 321 (114–1,144) | 376 (89–1,206) | 0.61 |
| Pre-treatment hemoglobin level, median (range), g/dL | 10.3 (6.4–16.3) | 11.3 (8.7–16.3) | 9.4 (6.4–13.7) | <0.001 |
| Follow-up, median (95% CI), months | 22 (19.7–30.9) | 23 (19.9–34.5) | 17 (13.5–32) | 0.42 |
Abbreviations: CALR, Calreticulin gene; CI, confidence interval; JAK2, Janus Kinase 2; SD, standard deviation.
Blood Res 2021;56:322~331 https://doi.org/10.5045/br.2021.2021101
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd